Modern vaccines and coronavirus infections
https://doi.org/10.17709/2409-2231-2020-7-4-11
Abstract
Vaccines represent an outstanding success story in modern medicine and are responsible for a huge reduction in morbidity and mortality worldwide. It is clear that improvements are necessary to enable the development of successful vaccines against some difficult pathogens, including human immunodeficiency virus and hepatitis C virus. This review is on recent advances in the development of new generation vaccines, as well as those developed using earlier time-tested technologies: live attenuated vaccines, inactivated vaccines, recombinant vaccines, subunit vaccines, virus-like particle-based vaccines, synthetic peptide vaccines, DNA vaccines and mRNA vaccines. However, many infections are still not preventable with the currently available vaccines and they represent a major cause of mortality worldwide — for example, severe acute respiratory syndrome coronavirus, middle east respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus 2 that causes coronavirus disease 2019 — COVID-19. As no effective treatment against COVID-19 is currently available, the best action is to develop vaccines to prevent the infection. The majority of candidate vaccines aim to induce neutralizing antibodies against the SARS-CoV-2. Multiple platforms areunder development. Some potential vaccine candidates have progressed to phase I and II clinical trials. In Russia, a vector vaccine based on adenovirus DNA, which has the SARS-CoV-2 virus gene embedded in it, is undergoing clinical trials.
About the Authors
Yu. A. Belikova
Obninsk Institute for Nuclear Power Engineering
Russian Federation
Russian Federation
Yulia A. Belikova – senior engineer of the biotechnology Center
1 Studgorodok, Obninsk 249040
SPIN: 4537-6304
AuthorID: 1066727
ResearcherID: AAJ-5141-2020
Yu. V. Samsonov
National Medical Research Radiological Center; P.A.Hertsen Moscow Oncology Research Institute – Branch of the National Medical Research Radiological Centre
Russian Federation
Russian Federation
Yuriy V. Samsonov – Cand. Sci. (Med.), Head of the Medical Care Coordination at the Coordination of activities of regional institutions Center of the Russian Federation in field of radiology and oncology, leading researcher of Russian Center of informational technologies and epidemical researches in oncology
3 2nd Botkinskiy travel, Moscow 125284
3 2nd Botkinskiy travel, Moscow 125284
AuthorID: 429105
E. V. Abakushina
Obninsk Institute for Nuclear Power Engineering; A.F.Tsyb Medical Radiological Research Center – Branch of the National Medical Research Radiological Center (A.F.Tsyb MRRC)
Russian Federation
Russian Federation
Elena V. Abakushina – Dr. Sci. (Med.), professor at the department of radionuclide medicine, medical faculty, department of biotechnology, senior researcher at the laboratory of clinical immunology,
1 Studgorodok, Obninsk 249040
4 Korolev str., Obninsk 249036
SPIN: 7015-3946
AuthorID: 158667
ResearcherID: А-8195-2016
Scopus Author ID: 15844847700
References
1. Myakinkova LL, Bukach OV, Logunova AV. Contemporary issues, challenges and future directions and trends in the field of vaccinology. Innovatics and Expert Examination: Scientific Works. 2015;1(14):96–109. (In Russian).
2. Zhang N, Jiang S, Du L. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014 Jun;13(6):761–774. https://doi.org/10.1586/14760584.2014.912134
3. Zhao J, Perera Ranawaka AP, Kayali G, Meyerholz D, Perlman S, Peiris M. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection. Journal of Virology. 2015;89(11):6117–6120. https://doi.org/10.1128/JVI.00446-15
4. Lan J, Deng Y, Chen H, Lu G, Wang W, Guo X, et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptorbinding domain as an antigen. PLoS One. 2014 Nov 18;9(11):e112602. https://doi.org/10.1371/journal.pone.0112602
5. Volz A, Kupke A, Song F, Jany S, Fux R, Shams-Eldin H, et al. Protective efficacy of recombinant modified vaccinia virus ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. Journal of Virology. 2015 Aug;89(16):8651– 8656. https://doi.org/10.1128/JVI.00614-15
6. Liu WJ, Zhao M, Liu K, Xu K, Wong G, Tan W, et al. T-cell immunity of SARS-CoV: Implications for vaccine developmen against MERS-CoV. Antiviral Research. 2017 Jan;137:82–92. https://doi.org/10.1016/j.antiviral.2016.11.006
7. He C, Qin M, Sun X. Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight. Acta Pharm Sin B. 2020 Jul;10(7):1175–1191. https://doi.org/10.1016/j.apsb.2020.05.009
8. Lambert P-H, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, et al. Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine. May 2020;38(31):4783–4791. https://doi.org/10.1016/j.vaccine.2020.05.064
9. Ma C, Su S, Wang J, Wei L, Du L, Jiang S. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. Microbes Infect. 2020 Aug;22(6–7):245– 253. https://doi.org/10.1016/j.micinf.2020.05.004
10. Pandey SC, Pande V, Sati D, Upreti S, Samant M. Vaccination strategies to combat novel corona virus SARS-CoV-2. Life Sci. 2020 Sep 1;256:117956. https://doi.org/10.1016/j.lfs.2020.117956
11. Shih H-I, Wu C-J, Tu Y-F, Chi C-Y. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines. Biomed J. 2020;43(4):341–354. https://doi.org/10.1016/j.bj.2020.05.021
12. Belete TM. A review on Promising vaccine development progress for COVID-19 disease. Vacunas. 2020 Dec;21(2):121– 128. https://doi.org/10.1016/j.vacun.2020.05.002
13. Kim E, Erdos G, Huang S, Kenniston TW, Balmert SC, Carey CD, et al. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020 May;55:102743. https://doi.org/10.1016/j.ebiom.2020.102743
14. Robson B. Computers and viral diseases. Preliminary bioinformatics studies on the design of a synthetic vaccine and a preventative peptidomimetic antagonist against the SARS-CoV-2 (2019-nCoV, COVID-19) coronavirus. Comput Biol Med. 2020;119:103670. https://doi.org/10.1016/j.compbiomed.2020.103670
15. Gupta T, Gupta SK. Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses. Int Immunopharmacol. 2020 Sep;86:106717. https://doi.org/10.1016/j.intimp.2020.106717
16. Alwis R de, Chen S, Gan ES, Ooi EE. Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development. EBioMedicine. 2020 May;55:102768. https://doi.org/10.1016/j.ebiom.2020.102768
17. Sarkar B, Ullah MA, Johora FT, Taniya MA, Araf Y. Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2). Immunobiology. 2020 May;225(3):151955. https://doi.org/10.1016/j.imbio.2020.151955
18. Hegarty PK, Kamat A, Zafirakis H, DiNardo A. BCG vaccination may be protective against Covid-19. Preprint. 2020 Mar. https://doi.org/10.13140/RG.2.2.35948.10880
19. Miller A, Reandelar MJ, Fasciglione K, Roumenova V, Li Y, Otazu GH. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. Preprint. 2020 Mar. https://doi.org/10.1101/2020.03.24.20042937
20. Curtis N, Sparrow A, Ghebreyesus TA, Netea M. Considering BCG vaccination to reduce the impact of COVID-19. The Lancet. 2020 May 16;395(10236):1545–1546. https://doi.org/10.1016/S0140-6736(20)31025-4
21. Pollard AJ, Finn A, Curtis N. Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Arch Dis Child. 2017 Nov;102(11):1077–1081. https://doi.org/10.1136/archdischild-2015-310282
22. WHO. Bacille Calmette-Guérin (BCG) vaccination and COVID-19. WHO Scientific Brief; 2020:1–2. Available at: https://www.who.int/news-room/commentaries/detail/bacille-calmette-guérin-(bcg)-vaccination-and-covid-19. Accessed: 30.07.2020.
23. Rajarshi K, Chatterjee A, Ray S. BCG vaccination strategy implemented to reduce the impact of COVID-19: Hype or Hope? Medicine in Drug Discovery. 24 May 2020;7:100049. https://doi.org/10.1016/j.medidd.2020.100049
24. N.F.Gamaleya Federal Research Centre of Epidemiology and Microbiology. Available at: http://www.gamaleya.org. Accessed: 30.07.2020. (In Russian).
25. I.M.Sechenov First Moscow State Medical University (Sechenov University). Available at: https://www.sechenov.ru/medicine/covid-19/. Accessed: 30.07.2020. (In Russian).
26. Group R-Pharm. Available at: http://r-pharm.com/ru/press-center/news/475. Accessed: 30.07.2020. (In Russian).
27. Finco O, Rappuoli R. Designing vaccines for the twenty-first century society. Frontiers in Immunology. January 2014;5:12. https://doi.org/10.3389/fimmu.2014.00012
28. Egorov AY. The challenges of creating a universal influenza vaccine. Microbiology Independent Research Journal. January 2016;3(1):1–12. (In Russian). https://doi.org/10.18527/2500-2236-2016-3-1-1-12
29. Yagovkin EA, Onishchenko GG, Popova AY, Ezhlova EB, Melnikova AA, Soloviev MY, et al. Condition and prospects of development of vaccines for specific prevention of enterovirus (nonpolio) infection. Epidemiology and Vaccinal Prevention. 2016;15(4):74–82. (In Russian). https://doi.org/10.31631/2073-3046-2016-15-4-74-82
30. Kondakova OA, Nikitin NA, Trifonova EA, Atabekov JG, Karpova OV. Rotavirus vaccines: new strategies and approaches. Bulletin of the Moscow University. Series 16. Biology. 2017;72(4):199–208. (In Russian).
31. Firstova VV, Karaulov AV, Dyatlov IA. Modern area of antiplague vaccine developments. Immunology. 2017;38(2):100–107. (In Russian). https://doi.org/10.18821/0206-4952-2017-38-2-100-107
32. Belyavtsev AN, Nikolaeva LI, Shastina NS, Koupriyanov VV. Immunogenic lipopeptides. Biomedicine. 2018;4:88-95. (In Russian).
33. Baryshnikova MA, Rudakova AA, Sokolova ZA, Burova OS, Kosobokova EN, Kosorukov VS. Evaluation of the antitumor efficacy of synthetic neoantigen peptides for the melanoma vaccine model. Russian Journal of Biotherapy. 2019;18(4):76–81. (In Russian). https://doi.org/10.17650/1726-9784-2019-18-4-76-81
34. Sereda AD, Imatdinov AR, Dubrovskaya OA, Kolbasov DV. Mechanisms of immune response and prospects for DNA vaccines against african swine fever (review). Agricultural Biology. 2017;52(6):1069–1082. (In Russian). https://doi.org/10.15389/agrobiology.2017.6.1069rus
35. Goryaev AA, Savkina MV, Obukhov YI, Merkulov VA, Olefir YV. DNA and RNA vaccines: current status, quality requirements and specific aspects of preclinical studies. BIOpreparations. Prevention, Diagnosis, Treatment. 2019;19(2):72–80. (In Russian). https://doi.org/10.30895/2221-996X-2019-19-2-72-80
36. Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods in Molecular Biology. 2015;1282:1–23. https://doi.org/10.1007/978-1-4939-2438-7_1
37. Wang Y-T, Landeras-Bueno S, Hsieh L-E, Terada Y, Kim K, Ley K, et al. Spiking Pandemic Potential: Structural and Immunological aspects of SARS-CoV-2. Trends in Microbiology. 2020 Aug;28(8):605–618. https://doi.org/10.1016/j.tim.2020.05.012
38. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613–620. https://doi.org/10.1038/s41423-020-0400-4
39. Temporary guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID-19)». Available at: https:// minzdrav.gov.ru/ministry/61/3/stranitsa-992/chetvertaya- redaktsiya. Accessed: 30.07.2020. (In Russian).
40. Gorenkov DV, Khantimirova LM, Shevtsov VA, Rukavishnikov AV, Merkulov VA, Olefir YV. An outbreak of a new infectious disease COVID-19: β-coronaviruses as a threat to global healthcare. BIOpreparations. Prevention, Diagnosis, Treatment. 2020;20(1):6–20. (In Russian). https://doi.org/10.30895/2221-996X-2020-20-1-6-20
41. Romanov B.K. Coronavirus disease COVID-2019. Safety and Risk of Pharmacotherapy. 2020;8(1):3–8. (In Russian). https://doi.org/10.30895/2312-7821-2020-8-1-3-8
42. Nikiforov VV, Suranova TG, Chernobrovkina TY, Yankovskaya YD, Burova SV. New coronavirus infection (COVID-19): clinical and epidemiological aspects. The Russian Archives of Internal Medicine. 2020;10(2):87–93. (In Russian). https://doi.org/10.20514/2226-6704-2020-10-2-87-93
43. Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. From SARS to MERS, thrusting coronaviruses into the spotlight. Viruses. 2019;11(1):59. https://doi.org/10.3390/v11010059
44. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020 Feb 15;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
45. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020 Feb 22;395(10224):565–574. https://doi.org/10.1016/S0140-6736(20)30251-8
46. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine. 2020 Feb 20;382(8):727-733. https://doi.org/10.1056/NEJMoa2001017
47. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. The New England Journal of Medicine. 2020 Mar 5;382(10):929–936. https://doi.org/10.1056/NEJMoa2001191
48. National Health Commission of the People’s Republic of China home page. Available at: https://www.nhc.gov.cn.Availableat: 30.07.2020.
49. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020 Feb 15;395(10223):507–513. https://doi.org/10.1016/S0140-6736(20)30211-7
50. Leung WK, To KF, Chan PK, Chan HL, Wu AK, Lee N, et al. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology. 2003 Oct;125(4):1011– 1017. https://doi.org/10.1016/s0016-5085(03)01215-0
51. Assiri A, McGeer A, Perl TM, Price CS, Rabeeah AA, Cummings DA, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. The New England Journal of Medicine. 2013;369:407–416. https://doi.org/10.1056/NEJMoa1306742
52. Shlyakho EV, Konradi AO, Arutyunov GP, Arutyunov AG, Bautin AE, Boytsov SA, et al. Guidelines for the diagnosis and treatment of circulatory diseases in the context of the COVID-19 pandemic. Russian Journal of Cardiology. 2020;25(3):3801. (In Russian). https://doi.org/10.15829/1560-4071-2020-3-3801
53. Shifman EM, Iosсovich AM, Ronenson AM, Kulikov AV. Overview of recommendations during pregnancy with COVID 19: What obstetric anesthetist need to know. Obstetric Anesthesia Digest. 2020;3(29):5–15. (In Russian). https://doi.org/10.24411/2686-8032-2020-00007
54. COVID19-2020.INFO. Statistics of coronavirus in the world. Available at: https://covid19-2020.info/. Accessed: 30.07.2020. (In Russian).
55. Chebotar IV, Shagin DA. On the unpredictability of outcomes of immunotherapy and preventive immunization against COVID-19. Bulletin of RSMU. 2020;2. (In Russian). https://doi.org/10.24075/vrgmu.2020.025
56. Everything is ready: Russia has the first coronavirus vaccine. Gazeta.Ru. Available at: https://www.gazeta.ru/army/2020/07/21/13160167.shtml. Accessed: 30.07.2020. (In Russian).
57. Antiviral defense. 1st Deputy defense Minister Ruslan Tsalikov – about the vaccine. The weekly «Arguments and Facts». Available at: https://aif.ru/society/army/protivovirusnaya_oborona_1-y_zamministra_oborony_ruslan_calikov_o_vakcine. Accessed: 30.07.2020. (In Russian).
58. The head of the RDIF explained that the Russian Federation does not make sense to steal data on the British COVID vaccine. Interfax. Available at: https://www.interfax.ru/russia/717743. Accessed: 30.07.2020. (In Russian).
59. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 15;396(10249):467–478. https://doi.org/10.1016/S0140-6736(20)31604-4
60. Zhu F-C, Guan X-H, Li Y-H, Huang J-Y, Jiang T, Hou L-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 15;396(10249):479–488. https://doi.org/10.1016/S0140-6736(20)31605-6
Review
For citations:
Belikova Yu.A., Samsonov Yu.V., Abakushina E.V. Modern vaccines and coronavirus infections. Research and Practical Medicine Journal. 2020;7(4):135-154. (In Russ.) https://doi.org/10.17709/2409-2231-2020-7-4-11
Views:
2892
Email this article 